ArticleScientific reports2017
Deep-sequencing of Marburg virus genome during sequential mouse passaging and cell-culture adaptation reveals extensive changes over time.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 26 citations in OpenAlex.
- A surrogate BSL2-compliant infection model recapitulating key aspects of human Marburg virus disease.Emerging microbes & infections · 2025Article
- Characterization of a STAT-1 Knockout Mouse Model for Machupo Virus Infection and Pathogenesis.Viruses · 2025Article
- Deep sequencing of serially passaged Sudan virus in guinea pigs uncovers adaptive mutations.Heliyon · 2025Article
- Genomic and transmission dynamics of the 2024 Marburg virus outbreak in Rwanda.Nature medicine · 2025Article
- Evaluating Countermeasures Against Marburg Virus Using a Mouse Model.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Genomic Evolution and Phylodynamics of the SpeciesPathogens (Basel, Switzerland) · 2024Review
- Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control.Signal transduction and targeted therapy · 2024Review
- Designing a novel and combinatorial multi-antigenic epitope-based vaccine "MarVax" against Marburg virus-a reverse vaccinology and immunoinformatics approach.Journal, genetic engineering & biotechnology · 2023Article
- Emergence of Marburg virus: a global perspective on fatal outbreaks and clinical challenges.Frontiers in microbiology · 2023Review
- Pathogenicity and virulence of Marburg virus.Virulence · 2022Review
- Article
- High-Throughput Screening Assay to Identify Small Molecule Inhibitors of Marburg Virus VP40 Protein.ACS infectious diseases · 2020Article
- Into the Deep (Sequence) of the Foot-and-Mouth Disease Virus Gene Pool: Bottlenecks and Adaptation during Infection in Naïve and Vaccinated Cattle.Pathogens (Basel, Switzerland) · 2020Article
- Novel Insights Into Immune Systems of Bats.Frontiers in immunology · 2020Review
- Marburg virus pathogenesis - differences and similarities in humans and animal models.Virology journal · 2019Review
- Consensus and variations in cell line specificity among human metapneumovirus strains.PloS one · 2019Article
- Recent advances in marburgvirus research.F1000Research · 2019Review
- Tools to study pathogen-host interactions in bats.Virus research · 2018Review
- Development and characterization of a guinea pig model for Marburg virus.Zoological research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Marburg virus (MARV) has caused outbreaks of filoviral hemorrhagic fever since its discovery in 1967. The largest and deadliest outbreak occurred in Angola in 2005, with 252 cases and 227 deaths. In 2014, we developed a mouse-adapted MARV, Angola variant through serial passaging in mice. The mouse-adapted MARV exhibits many of the hallmarks of MARV disease in humans. By applying deep-sequencing to every passage of the virus, we are able to study virus evolution in this host with surprising precision. We show that two regions go through substantial changes: the intergenic region between NP and VP35, as well as the first 100 amino acids of the VP40 protein. Our results also reveal that there were profound changes during the production of the final virus stock in cell culture. Overall, our results show that a handful of regions carry most of the mutations acquired during the adaptation of the virus to a new host and that many mutations become fixed very early during the adaptation process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.